Hims slips after market despite earnings, revenue beat
whipsawed in after-hours trading despite reporting earnings results for the first three months of the year that blew Wall Street expectations out of the park. It reported earnings per share of $0.20, ...
Is a Hims & Hers short squeeze brewing?
Once it was clear that ’ ability to sell exact copies of Ozempic and Wegovy was coming to an end, the short sellers came running. While that may have been a fruitful trade in the beginning, recent eve...
Eli Lilly slips after slashing full-year guidance
slipped in premarket trading after it beat Wall Street estimates but cut its profit guidance for the year. The company reported adjusted earnings per share of $3.34, compared to the $3.26 analysts pol...
Moderna posts earnings beat but stock slips because it still doesn’t really have a product to sell
slipped in premarket trading despite beating Wall Street earnings estimates, as sales for the COVID-19 vaccine, its largest revenue driver, have slowed. Moderna reported a loss per share of $2.52, bet...
Hims & Hers surges after announcing partnership with Ozempic maker Novo Nordisk
shot up 30% in premarket trading after it announced a collaboration with , the drugmaker that manufactures Ozempic and Wegovy. In a Tuesday morning announcement , the telehealth company said that “as ...
Pfizer beats earnings estimates thanks to cost cuts
Pfizer beat Wall Street earnings estimates for the first three months of this year, fueled largely by an aggressive cost-cutting campaign. reported adjusted earnings per share of $0.92, higher than th...
Botox sales slip as consumer sentiment wrinkles
As more economists raise their recession forecast and consumer sentiment wanes, wrinkles and thin lips might be the least of our worries. , the largest Botox manufacturer in the US, reported on Friday...
AbbVie rises as it beats Wall Street estimates, raises 2025 outlook
raised its profit outlook for 2025 after reporting sales and profit that beat Wall Street estimates, driven largely by the success of its newer immunology drugs. The company reported $13.3 billion in ...
Gilead slips after sales miss
Gilead Sciences slipped 3% in after-hours trading after it reported sales that missed Wall Street estimates, though earnings came in better than expected. The company reported $6.7 billion in sales, c...
Merck says it will eat $200 million in tariff costs
German pharmaceutical giant said in a Thursday earnings report that it will take a $200 million hit in added costs this year from the tariffs implemented by the US so far, leading it to tweak down its...
Philip Morris already sold enough Zyn in 2025 to span Route 66
Tobacco giant reported earnings on Wednesday that beat Wall Street estimates, bolstered by the wild success of its Zyn nicotine pouches. The company rose after it reported an earnings per share of $1...
Eli Lilly sues telehealth sites selling copycat Zepbound
sued four telehealth platforms selling copycat versions of its blockbuster weight-loss drug Zepbound, a move that could foreshadow more legal actions against these kinds of companies. In four separate...
FDA issues warning on hair-loss treatment sold on Hims & Hers
The Food and Drug Administration issued a warning over topical finasteride, a topical hair-loss treatment sold by telehealth providers like . The FDA has approved two oral finasteride treatments but h...
Novo Nordisk slumps following trial results for Eli Lilly’s weight-loss pill
Novo Nordisk, the Danish maker of Ozempic and Wegovy, fell almost 10% early on Tuesday — its first trading session since rival unveiled strong trial results for its experimental weight-loss pill last...
Eli Lilly rises after weight-loss pill succeeds in trials
once-daily weight-loss pill, orforglipron, succeeded in early trials with results similar to popular GLP-1 injections on the market now, bolstering the company’s lead in the race to make the next weig...
Are importers front-running pharma tariffs?
Pharmaceutical products rushed into US ports in the first two months of this year as the threat of tariffs on the industry looms. Pharmaceutical products imported to the US in January and February rea...
Novo Nordisk, Eli Lilly rise after Pfizer scraps obesity pill
will stop developing a weight-loss pill after it was linked to liver injury in one patient enrolled in a clinical trial, giving a boost to and , which are fighting to keep their place at the center o...
Compounding pharmacy says Eli Lilly’s cease and desist letter means “nothing”
OrderlyMeds, an online pharmacy that sells compounded versions of blockbuster weight-loss drug Zepbound, said the drugmaker’s cease and desist letter means “nothing.” The Food and Drug Administration...
Pharma stocks sink on threats that they won’t be spared from tariffs much longer
Pharmaceutical stocks are dipping after President Trump suggested they won’t be spared by tariffs for much longer. Drugmakers were spared from the first round of tariffs that went into effect on Wedne...
After saying overseas drugmakers would have a “big tax to pay,” Trump spares pharmaceuticals from reciprocal tariffs
After lots of bluster about European countries having the pharmaceutical industry in their grasp, the White House spared pharmaceutical products from its wide-ranging tariff spree — at least for now. ...